Oral oncology最新文献

{"title":"Sensitivity of post-treatment surveillance in detecting recurrence and metastasis in surgically treated HPV-positive oropharyngeal squamous cell carcinoma patients","authors":"Agnes Q Zhu ,&nbsp;Claire E Cassianni ,&nbsp;Travis Haller ,&nbsp;Thomas J. O’Byrne ,&nbsp;Pablo Ochoa ,&nbsp;Tissiana Vallecillo ,&nbsp;Andrew Pumford ,&nbsp;Felicia Olawuni ,&nbsp;Eric J Moore ,&nbsp;Daniel L Price ,&nbsp;Kendall K Tasche ,&nbsp;Linda X Yin ,&nbsp;Daniel J Ma ,&nbsp;Scott C Lester ,&nbsp;Mauricio Gamez ,&nbsp;Michelle A Neben Wittich ,&nbsp;Katharine A Price ,&nbsp;Kathryn M Van Abel ,&nbsp;David M Routman","doi":"10.1016/j.oraloncology.2025.107767","DOIUrl":"10.1016/j.oraloncology.2025.107767","url":null,"abstract":"<div><h3>Introduction</h3><div>There is a lack of data regarding the appropriate surveillance of HPV(+)OPSCC. Our study aims to determine the sensitivity of patient symptoms, physical exam findings, and imaging in identifying recurrence and disease progression.</div></div><div><h3>Methods</h3><div>Mayo Clinic IRB (22–000684) approval was obtained, and the departmental REDCap database was queried to identify all HPV(+)OPSCC patients from 01/01/2006 to 12/31/2021 at our tertiary care center. Surgically treated patients with pathologic specimens positive for HPV (confirmed with in-situ hybridization (ISH) and/or p16 immuno-histochemistry) without evidence of distant metastatic disease at diagnosis were included.<!--> <!-->Sensitivity, specificity, PPV, and NPV of patient symptoms, physical exam findings, and imaging for disease progression were assessed both overall and at each time point.</div></div><div><h3>Results</h3><div>142/1142 patients experienced disease progression. 70% of patients with disease progression were detected within the first two years of surveillance. 79 patients with disease progression were detected via routine surveillance imaging, 34 via patient-reported symptoms, and 5 via physical exam.</div><div>Routine surveillance imaging was the most sensitive method of detection for locoregional recurrence (sensitivity 92.3%, PPV 6.5%, NPV 42.9%) and distant metastasis (sensitivity 100%, PPV 6.7%, NPV 100.0%). Patient symptoms in aggregate had a 73.1% sensitivity for detecting locoregional recurrence (PPV 8.7%, NPV 95.4%); however no individual symptom had a sensitivity over 30%. Physical exam findings were the least sensitive method of detection.</div></div><div><h3>Conclusion</h3><div>Our findings demonstrate that the majority of recurrences are detected within the first two years of surveillance. Routine surveillance imaging is the most sensitive modality for detecting disease progression as compared to patient symptoms or physical exam findings. Additional studies integrating newer technologies, such as ctHPVDNA. into surveillance are needed.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107767"},"PeriodicalIF":3.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145420249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durable complete response to tislelizumab plus cetuximab in a 94-year-old patient with advanced lower lip squamous cell carcinoma: A case report and literature review","authors":"Shi-Qiong Zhou ,&nbsp;Sen Zhang ,&nbsp;Qing-Hua Ke","doi":"10.1016/j.oraloncology.2025.107765","DOIUrl":"10.1016/j.oraloncology.2025.107765","url":null,"abstract":"<div><h3>Background</h3><div>Lip squamous cell carcinoma (SCC) is a rare subtype of head and neck squamous cell carcinoma (HNSCC), accounting for approximately 1 % of all oral malignancies. Unlike other oral SCCs (e.g., tongue or buccal SCC), lip SCC has distinct epidemiological features: it shows a stronger association with chronic sun exposure (especially ultraviolet radiation) and a lower correlation with smoking/alcohol consumption. It is more common in elderly males, and advanced cases with lymph node metastasis are associated with poor prognosis. The treatment of advanced lip SCC in elderly patients is uniquely challenging due to its anatomical location (functional and aesthetic importance), which makes aggressive therapies like surgery more likely to cause functional impairment (e.g., difficulty in mouth opening or speech) and poor tolerance to such therapies due to comorbidities [1–3].</div></div><div><h3>Case summary</h3><div>A 94-year-old female patient presented with a progressively enlarging mass on the right lower lip, which was diagnosed as poorly differentiated squamous cell carcinoma with neck lymph node metastasis (cT4N2M0). Due to her advanced age and late-stage disease, she was not eligible for surgery, radiotherapy, or chemotherapy. She received combination therapy with tislelizumab (200 mg intravenously every 3 weeks) and cetuximab (400 mg/m² intravenously every 2 weeks) starting from November 27, 2024. Significant improvement of the lip mass was observed after treatment, and complete response was achieved on January 8, 2025, after two cycles of treatment. Consolidation therapy was continued for six months, with no recurrence or metastasis during follow-up. As of July 31, 2025 (6 months after initial treatment), the patient remains in complete response with regular follow-up. Immunohistochemical analysis showed PD-L1 positivity with a combined positive score (CPS) of 80, which may predict a favorable response to immunotherapy.</div></div><div><h3>Conclusion</h3><div>This case demonstrates that the combination of tislelizumab and cetuximab can achieve remarkable efficacy in elderly patients with advanced lip SCC, even without surgery, radiotherapy, or chemotherapy. PD-L1 high expression (CPS = 80) may serve as a valuable predictive biomarker for immunotherapy response in such cases. Six months follow-up confirms the durability of the response, supporting the potential of this regimen in extreme elderly populations.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107765"},"PeriodicalIF":3.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145420250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-surgery billing in head and neck free-flap reconstruction: trends and reimbursement patterns under medicare","authors":"Daniel Gilmore ,&nbsp;Nolan B. Seim ,&nbsp;Lauren E. Miller","doi":"10.1016/j.oraloncology.2025.107763","DOIUrl":"10.1016/j.oraloncology.2025.107763","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107763"},"PeriodicalIF":3.9,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145409636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: “Patterns of care in de‑novo oligo‑metastatic and oligo‑recurrent head and neck cancers: A HNCIG survey” (Oral oncology)","authors":"Nengjun Xiang ,&nbsp;Wentao Li","doi":"10.1016/j.oraloncology.2025.107749","DOIUrl":"10.1016/j.oraloncology.2025.107749","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107749"},"PeriodicalIF":3.9,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145374456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The low evidence to treat elderly patients with head and neck cancer","authors":"Beatriz Bertin ,&nbsp;Luiz Paulo Kowalski ,&nbsp;Leandro Luongo Matos","doi":"10.1016/j.oraloncology.2025.107764","DOIUrl":"10.1016/j.oraloncology.2025.107764","url":null,"abstract":"<div><div>Treatment of head and neck cancer in older patients is particularly complex, as they are more prone to side effects and treatment-related toxicity due to age-related physiological changes. Nevertheless, they should still receive care based on the best available standards and protocols, since alternative approaches may increase the risk of treatment failure and mortality. The core issue lies in the lack of evidence-based protocols tailored to the specific needs of older patients, as most clinical trials seam to focus on younger populations. The objective of this study was to determine the rate of patients over 65 years of age included in clinical trials of treatments for head and neck cancer. In this context, the study aims to shed light on the proportion of clinical evidence that can be safely extrapolated to the treatment of older patients with head and neck cancer. To achieve this, we analyzed the age distribution of patients enrolled in clinical trials cited by the National Comprehensive Cancer Network (NCCN) in the NCCN Guidelines Version 2.2025: Head and Neck Cancers. Less than one-fourth of patients enrolled in the NCCN-referenced clinical trials were over 65 years of age, reinforcing concerns about the applicability of current protocols to this population. To address this gap, the most effective strategy is to promote the generation and dissemination of evidence-based data that actively includes older adults worldwide.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107764"},"PeriodicalIF":3.9,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145374455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic factors of head and neck osteosarcoma: A 10-year retrospective study from a single institute","authors":"Pengfei Zhao ,&nbsp;Qingcheng Shen ,&nbsp;Jieyu Wang ,&nbsp;Yiming Chen","doi":"10.1016/j.oraloncology.2025.107759","DOIUrl":"10.1016/j.oraloncology.2025.107759","url":null,"abstract":"<div><h3>Background</h3><div>Head and neck osteosarcoma (HNOS) is a rare malignant bone tumor, comprising approximately 10 % of all osteosarcoma cases, with the mandible being the most commonly affected site. Surgery remains the cornerstone of treatment, and achieving negative margins is critical for improved prognosis. However, due to the rarity of HNOS, most studies suffer from limited sample sizes. This retrospective cohort study aims to evaluate the impact of various clinical and treatment factors on patient outcomes over 10 years.</div></div><div><h3>Materials and methods</h3><div>A retrospective study was conducted. Data were collected from patients diagnosed with osteosarcoma and treated with primary tumor surgery at the Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People’s Hospital, between 2009 and 2018. Demographic, clinical, pathological, and treatment variables were analyzed using univariate and multivariate methods to assess overall survival (OS), disease-free survival (DFS), local recurrence (LR), and metastasis (MT).</div></div><div><h3>Result</h3><div>247 patients met the inclusion criteria, with 209 included in the follow-up analysis. Mandibular location, primary tumors, and negative surgical margins were significantly associated with improved OS and DFS. The female sex was linked to a lower risk of LR, while pathological grade III tumors predicted poorer OS and DFS. Positive margins significantly worsened OS and DFS and increased LR risk. Chemotherapy or radiotherapy did not significantly affect survival outcomes.</div></div><div><h3>Conclusion</h3><div>Mandibular location, primary tumors, and negative margins are favorable prognostic factors for HNOS. Pathological grade III and positive margins indicate poorer outcomes. Multimodal treatments did not demonstrate significant survival benefits.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107759"},"PeriodicalIF":3.9,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145364172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term health-related quality of life following segmental mandibulectomy and osseous reconstruction","authors":"Johannes N. van der Lely ,&nbsp;Denzel Chin ,&nbsp;Laurentina M.H. van der Lubbe ,&nbsp;Anthony M. Tonsbeek ,&nbsp;Gerda M. Verduijn ,&nbsp;Caroline A. Hundepool ,&nbsp;Eveline M.L. Corten ,&nbsp;Hetty Mast ,&nbsp;Eppo B. Wolvius ,&nbsp;Brend P. Jonker ,&nbsp;Marc A.M. Mureau","doi":"10.1016/j.oraloncology.2025.107762","DOIUrl":"10.1016/j.oraloncology.2025.107762","url":null,"abstract":"<div><h3>Background</h3><div>Evaluation of long-term health-related quality of life (HRQOL) is essential for optimizing functional and psychological outcomes after major head and neck surgery. Because research on this topic is scarce, this study aimed to assess long-term HRQOL in patients following segmental mandibulectomy and osseous reconstruction.</div></div><div><h3>Methods</h3><div>A retrospective, cross-sectional study was performed, including all consecutive patients who underwent segmental mandibulectomy and subsequent osseous reconstruction between 1993 and 2024. The primary outcome was HRQOL, assessed using the FACE-Q Head and Neck Cancer Module. Descriptive statistics summarized FACE-Q domain scores. Multivariable analyses identified associations between clinical variables and HRQOL.</div></div><div><h3>Results</h3><div>Of all 333 reconstructed patients, 117 were still alive and eligible for inclusion of whom 74 responded (response, 63 %) with a mean follow-up of 7.6 years (SD, 6.3) after surgery. In the long term, functional domains of the FACE-Q were most affected while psychological functioning scores remained relatively more favorable. Radiotherapy was significantly associated with lower scores in the domains of salivation (β = −28.6; p = 0.008), smile (β = −20.4; p = 0.046), and swallowing (β = −27.8; p = 0.004). Anterior mandibular defects (Brown class III-IV) were associated with poorer speech outcomes (β = −18.2; p = 0.012). Higher age at surgery was associated with poorer eating and drinking scores (β = −0.5; p = 0.008), while dental rehabilitation was associated with better scores (β = 11.7; p = 0.016).</div></div><div><h3>Conclusion</h3><div>At long-term follow-up after segmental mandibulectomy and osseous reconstruction, various functional domains of HRQOL were affected, while psychological functioning scores seemed to remain relatively more favorable. Targeting modifiable factors may enhance long-term HRQOL in this population.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107762"},"PeriodicalIF":3.9,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145364171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: Developing a predictive nomogram model for incidence of adverse outcomes in oral and maxillofacial tumor patients undergoing free flap reconstruction","authors":"Thangapandi Marudhupandi","doi":"10.1016/j.oraloncology.2025.107751","DOIUrl":"10.1016/j.oraloncology.2025.107751","url":null,"abstract":"<div><div>The study by Lin et al. presents a valuable predictive nomogram model for evaluating adverse outcomes in patients with oral and maxillofacial tumors undergoing free flap reconstruction. By combining clinical and perioperative variables, the authors provide a tool to stratify patient risk and inform surgical decision-making. The findings are clinically relevant, considering the complexity and potential complications of free flap reconstruction. While the model shows promising accuracy, external validation and the addition of further parameters, such as nutritional status, systemic inflammation markers, and quality-of-life outcomes, would improve its usefulness. This work makes a significant contribution to surgical oncology by advancing personalized risk prediction and providing evidence-based support for perioperative management in complex head and neck reconstructions.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107751"},"PeriodicalIF":3.9,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145364173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of oropharyngeal squamous cell carcinoma among patients with lymphoproliferative disorders","authors":"Marta M. Williams ,&nbsp;Glenn J. Hanna ,&nbsp;Rosh K. Sethi ,&nbsp;Eleni M. Rettig","doi":"10.1016/j.oraloncology.2025.107761","DOIUrl":"10.1016/j.oraloncology.2025.107761","url":null,"abstract":"<div><h3>Introduction</h3><div>Human Papillomavirus (HPV) causes most oropharynx squamous cell carcinomas (OPCs) in the U.S. Immune suppression is associated with both HPV infection and lymphoproliferative disorders (LPD), yet little is known about outcomes among patients with both diagnoses. This study evaluated clinical characteristics and survival in patients diagnosed with both OPC and LPD.</div></div><div><h3>Methods</h3><div>We conducted a retrospective study of patients evaluated at Dana-Farber Cancer Institute from 2001 to 2020 with diagnoses of both OPC and LPD (leukemia or lymphoma). Demographic and clinical data were compared by order of diagnosis, and overall survival (OS) from OPC diagnosis was analyzed.</div></div><div><h3>Results</h3><div>Among 53 patients, 38 % were diagnosed with OPC first and 62 % with LPD first. Median ages at OPC and LPD diagnoses were 62 and 61 years, respectively. Fiftyseven percent of OPCs were HPV-positive. Patients with prior LPD were more likely to undergo surgery (51 % vs 30 %) and less likely to receive radiation (66 % vs 100 %) for OPC (p = 0.03), despite similar disease stage. Patients with HPV-negative OPC had significantly worse OS than those with HPV-positive tumors (HR 5.6, 95 %CI2.2–14.3). Among HPV-positive OPC patients, those with prior LPD had lower 5-year OS (58 %) than typically reported in immunocompetent cohorts. HPV-positive OPC patients with previous LPD diagnosis tended to have shorter OS after OPC diagnosis than those diagnosed with LPD after OPC (HR = 1.9, 95 %CI = 0.6–5.4).</div></div><div><h3>Conclusions</h3><div>A prior LPD diagnosis influences treatment strategies and may impact survival in patients with OPC. While HPV-positive status remains a favorable prognostic factor, long-term outcomes appear diminished in this population.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107761"},"PeriodicalIF":3.9,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145355601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining prognosis and Personalizing Therapy: A Step Forward with Machine learning in HPV-Associated head and neck cancer","authors":"Rupsa Das ,&nbsp;Satya Ranjan Misra ,&nbsp;Satya Sundar Gajendra Mohapatra","doi":"10.1016/j.oraloncology.2025.107752","DOIUrl":"10.1016/j.oraloncology.2025.107752","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107752"},"PeriodicalIF":3.9,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145355683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}